These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 23525713)

  • 1. Science to practice: Molecular targeting with SPECT/CT and MR imaging in oncology--integration of functional and structural imaging.
    Subramaniam RM
    Radiology; 2013 Apr; 267(1):1-3. PubMed ID: 23525713
    [No Abstract]   [Full Text] [Related]  

  • 2. Orthotopic pleural mesothelioma in mice: SPECT/CT and MR imaging with HER1- and HER2-targeted radiolabeled antibodies.
    Nayak TK; Bernardo M; Milenic DE; Choyke PL; Brechbiel MW
    Radiology; 2013 Apr; 267(1):173-82. PubMed ID: 23329660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo imaging of therapy response to a novel pan-HER antibody mixture using FDG and FLT positron emission tomography.
    Nielsen CH; Jensen MM; Kristensen LK; Dahlman A; Fröhlich C; Jacobsen HJ; Poulsen TT; Lantto J; Horak ID; Kragh M; Kjaer A
    Oncotarget; 2015 Nov; 6(35):37486-99. PubMed ID: 26460961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer.
    Heskamp S; Laverman P; Rosik D; Boschetti F; van der Graaf WT; Oyen WJ; van Laarhoven HW; Tolmachev V; Boerman OC
    J Nucl Med; 2012 Jan; 53(1):146-53. PubMed ID: 22173842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body MR or PET-CT?
    Schmidt GP
    Eur J Radiol; 2012 Sep; 81 Suppl 1():S142-3. PubMed ID: 23083566
    [No Abstract]   [Full Text] [Related]  

  • 6. PET/MRI with diagnostic MR sequences vs PET/CT in the detection of abdominal and pelvic cancer.
    Xin J; Ma Q; Guo Q; Sun H; Zhang S; Liu C; Zhai W
    Eur J Radiol; 2016 Apr; 85(4):751-9. PubMed ID: 26971419
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging EGFR and HER2 by PET and SPECT: a review.
    Corcoran EB; Hanson RN
    Med Res Rev; 2014 May; 34(3):596-643. PubMed ID: 24037872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomography/CT versus MRI in liver metastasis: is there a winner?
    Grassetto G; Maffione AM; Rubello D
    J Med Imaging Radiat Oncol; 2014 Oct; 58(5):529-31. PubMed ID: 25287485
    [No Abstract]   [Full Text] [Related]  

  • 9. From PET/CT to PET/MRI: advances in instrumentation and clinical applications.
    Hu Z; Yang W; Liu H; Wang K; Bao C; Song T; Wang J; Tian J
    Mol Pharm; 2014 Nov; 11(11):3798-809. PubMed ID: 25058336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
    Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
    Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET/MRI: Emerging Clinical Applications in Oncology.
    Fraum TJ; Fowler KJ; McConathy J
    Acad Radiol; 2016 Feb; 23(2):220-36. PubMed ID: 26521689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical PET/MR Imaging in Oncology: Future Perspectives.
    Kjær A; Torigian DA
    PET Clin; 2016 Oct; 11(4):489-93. PubMed ID: 27593252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New challenges and perspectives in nuclear medicine imaging].
    Borbély K
    Magy Onkol; 2014 Dec; 58(4):232-8. PubMed ID: 25517440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET/CT, MR, and PET/MR in Lymphoma and Melanoma.
    Schwenzer NF; Pfannenberg AC
    Semin Nucl Med; 2015 Jul; 45(4):322-31. PubMed ID: 26050659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer.
    Xavier C; Vaneycken I; D'huyvetter M; Heemskerk J; Keyaerts M; Vincke C; Devoogdt N; Muyldermans S; Lahoutte T; Caveliers V
    J Nucl Med; 2013 May; 54(5):776-84. PubMed ID: 23487015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overview of positron emission tomography, hybrid positron emission tomography instrumentation, and positron emission tomography quantification.
    Kwee TC; Torigian DA; Alavi A
    J Thorac Imaging; 2013 Jan; 28(1):4-10. PubMed ID: 23249967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent Advances in Imaging of Small and Large Bowel.
    Das CJ; Manchanda S; Panda A; Sharma A; Gupta AK
    PET Clin; 2016 Jan; 11(1):21-37. PubMed ID: 26590441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases.
    Fortuin AS; Deserno WM; Meijer HJ; Jager GJ; Takahashi S; Debats OA; Reske SN; Schick C; Krause BJ; van Oort I; Witjes AJ; Hoogeveen YL; van Lin EN; Barentsz JO
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):712-8. PubMed ID: 22417806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Multimodality equipment. A new vision in imaging diagnosis].
    Lapeña Gutiérrez L
    An R Acad Nac Med (Madr); 2010; 127(3):445-54; discussion 454-8. PubMed ID: 22263342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [MRI and PET in Alzheimer's disease].
    Matsunari I
    No Shinkei Geka; 2012 Dec; 40(12):1051-63. PubMed ID: 23362554
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.